Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.35 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6052877 | 1.00 | LAP3 (0.35) | LAP3ALOX5SLC15A1HTTEPHX1 | |
| SCHEMBL6342303 | 1.00 | LAP3 (0.35) | LAP3ALOX5SLC15A1HTTEPHX1 | |
| SCHEMBL3131488 | 0.81 | HPGD (0.38) | ALOX5SLC15A1EPHX1HPGD | |
| SCHEMBL8411597 | 0.81 | FAAH (0.41) | LAP3FAAHABCB1HPGDTSHR | |
| SCHEMBL6342050 | 0.80 | ALOX5 (0.36) | LAP3ALOX5SLC15A1EPHX1 | |
| SCHEMBL6164405 | 0.78 | LAP3 (0.36) | LAP3ALOX5L3MBTL1 | |
| SCHEMBL8411083 | 0.77 | MMP9 (0.43) | HPGD | |
| SCHEMBL6354283 | 0.76 | UBE2N (0.36) | HPGDTSHR | |
| SCHEMBL28026869 | 0.75 | EPHX1 (0.46) | SLC15A1EPHX1L3MBTL1SRR | |
| SCHEMBL27660866 | 0.75 | EPHX1 (0.46) | SLC15A1EPHX1L3MBTL1SRR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6992101-B2 | N-(indole-2-carbonyl) and H-thieno[2,3-b]pyrrole-5-carboxamide anti-diabetic agents | PFIZER, INC. (US) | 2006-01-31 | — | — | US | disclosed |
| EP-1562899-A2 | N-(INDOLE-2-CARBONYL)AMIDES AS ANTI-DIABETIC AGENTS | Pfizer Products Inc. (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20040157907-A1 | Anti-diabetic agents | PFIZER INC | 2004-08-12 | — | — | US | disclosed |
| WO-2004041780-A2 | N-(INDOLE-2-CARBONYL) AMIDES AS ANTI-DIABETIC AGENTS | PFIZER PRODUCTS INC. (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157907-A1 | Anti-diabetic agents | GPR119, INSR, IRS1 | LAP3 2259/4885ALOX5 933/4885SLC15A1 715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.